Research programme: GP41 inhibitors - Locus Pharmaceuticals

Drug Profile

Research programme: GP41 inhibitors - Locus Pharmaceuticals

Alternative Names: GP41 inhibitors research programme - Locus Pharmaceuticals

Latest Information Update: 21 Jan 2010

Price : $50

At a glance

  • Originator Locus Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Viral infections

Most Recent Events

  • 22 Jun 2005 This programme is still in active development - (BIO-2005)
  • 22 Jun 2004 The gp41 fusion inhibitors programme is available for licensing (
  • 27 Feb 2003 Preclinical trials in Viral infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top